Prophylaxis of venous thromboembolism in cancer patients

References

• Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–634.
   PubMed Web of Science ®Google Scholar
• Farge-Bancel D, Bounameaux H, Brenner B, et al., et al. Implementing thrombosis guidelines in cancer patients: a review. Rambam Maimonides Med J. 2014;5(4):e0041.
   Google Scholar
• Frere C, Debourdeau P, Hij A, et al. Therapy for cancer-related thromboembolism. Semin Oncol. 2014;41(3):319–338.
   PubMed Web of Science ®Google Scholar
• Horsted F, West J, Grainge MJ, et al. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001275.
   PubMed Web of Science ®Google Scholar
• Mandala M, Falanga A, Roila F, et al. Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2011;22(Suppl 6):vi85–92.
   PubMedGoogle Scholar
• Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e227S- 77S.
   PubMed Web of Science ®Google Scholar
• Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e195S- 226S.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–656.
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines for Cancer-Associated Venous Thromboembolic disease [Internet]. [ cited 2016 Jan 1]. Available from: https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/vte.pdf
   Google Scholar
• Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11(1):56–70.
   PubMed Web of Science ®Google Scholar
• Kakkar VV, Balibrea JL, Martínez-González J, et al. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost. 2010;8(6):1223–1229.
   PubMed Web of Science ®Google Scholar
• Vedovati MC, Becattini C, Rondelli F, et al. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg. 2014;259(4):665–669.
   PubMed Web of Science ®Google Scholar
• Carrier M, Khorana AA, Moretto P, et al. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med. 2014;127(1):82–6.e1.
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Carrier M, Lyman GH, et al. Subcommittee on haemostasis and malignancy. Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2014;12(10):1746–1749.
   PubMed Web of Science ®Google Scholar
• Zwicker JI, Rojan A, Campigotto F, et al. Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study. J Clin Oncol. 2014;32(17):1792–1796.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Tapson VF, Bergmann J-F, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387–394.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Dalal M, Lin J, et al. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119(3):648–655.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943–949.
   PubMed Web of Science ®Google Scholar
• Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601–609.
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Porreca E, Otten H-M, et al. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2014. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008500.pub3/abstract
   Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414–423.
   PubMed Web of Science ®Google Scholar
• Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer Oxf Engl. 2012;48(9):1283–1292.
   PubMed Web of Science ®Google Scholar
• Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol. 2015;33(18):2028–2034.
   PubMed Web of Science ®Google Scholar
• Macbeth F, Noble S, Evans J, et al. Randomized phase iii trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. J Clin Oncol. 2016;34(5):488–494.
   PubMed Web of Science ®Google Scholar
• Haas SK, Freund M, Heigener D, et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb. 2012;18(2):159–165.
   PubMed Web of Science ®Google Scholar
• Panizo E, Alfonso A, García-Mouriz A, et al. Factors influencing the use of thromboprophylaxis in cancer outpatients in clinical practice: A prospective study. Thromb Res. 2015;136(6):1145–1148.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–4907.
   PubMed Web of Science ®Google Scholar
• Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377–5382.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Streiff MB, Lau BD, et al. Impact of a venous thromboembolism prophylaxis smart order set: improved compliance, fewer events. Am J Hematol. 2013;88(7):545–549.
   PubMed Web of Science ®Google Scholar
• Lustig DB, Rodriguez R, Wells PS. Implementation and validation of a risk stratification method at The Ottawa hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis. Thromb Res. 2015;136(6):1099–1102.
   PubMed Web of Science ®Google Scholar